» Articles » PMID: 7478537

The POU Domain Transcription Factor Brn-2: Elevated Expression in Malignant Melanoma and Regulation of Melanocyte-specific Gene Expression

Overview
Journal Oncogene
Date 1995 Nov 16
PMID 7478537
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Previous work has shown that melanoma cell lines express a distinct octamer binding protein. Given the role of octamer-binding proteins in cell differentiation and development, the role this factor is a key issue in understanding melanocyte differentiation and transformation. Using a proteolytic clipping assay, we show that the melanoma-specific octamer factor is Brn-2/N-Oct3, a POU domain protein previously known to be expressed in adult brain and in the developing nervous system. N-Oct3 mRNA was detected in a range of human melanoma cell lines and was around 10-fold elevated compared to normal human melanocytes while mRNA for Brn-2 was also detected in a mouse melanoblast cell line. Expression of Brn-2/N-Oct3, in melanoma cells in cotransfection assays activated the expression of the MHC class II DR alpha promoter but repressed the activity of the melanocyte-specific tyrosinase promoter. Repression correlated with Brn-2/N-Oct3 binding in a mutually exclusive fashion with basic-helix-loop-helix-leucine-zipper (bHLH-LZ) transcription factor USF in vitro and with Brn-2 expression preventing activation of the tyrosinase promoter by the bHLH-LZ factor Microphthalmia in vivo. The potential role of Brn-2/N-Oct3 in melanocyte differentiation and gene expression is discussed.

Citing Articles

Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.

Neuendorf H, Simmons J, Boyle G Front Cell Dev Biol. 2023; 11:1183328.

PMID: 37181747 PMC: 10169659. DOI: 10.3389/fcell.2023.1183328.


Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype.

Polubothu S, Zecchin D, Al-Olabi L, Lionarons D, Harland M, Horswell S Genet Med. 2021; 23(9):1636-1647.

PMID: 34145395 PMC: 8460442. DOI: 10.1038/s41436-021-01204-y.


Transcriptional regulators and alterations that drive melanoma initiation and progression.

Gupta R, Janostiak R, Wajapeyee N Oncogene. 2020; 39(48):7093-7105.

PMID: 33024276 PMC: 7695596. DOI: 10.1038/s41388-020-01490-x.


BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.

Herbert K, Binet R, Lambert J, Louphrasitthiphol P, Kalkavan H, Sesma-Sanz L Genes Dev. 2019; 33(5-6):310-332.

PMID: 30804224 PMC: 6411009. DOI: 10.1101/gad.314633.118.


In silico studies of the interaction between BRN2 protein and MORE DNA.

do Vale Coelho I, Arruda D, Taranto A J Mol Model. 2016; 22(9):228.

PMID: 27568376 DOI: 10.1007/s00894-016-3078-x.